Trinity Capital Inc. Provides $40 Million Term Loan to Taysha Gene Therapies
PHOENIX, Dec. 19, 2023 /PRNewswire/ — Trinity Capital Inc. (NASDAQ: TRIN) (“Trinity”), a leading provider of diversified financial solutions to growth-stage companies, today announced the commitment of $40 million in term loans to Taysha Gene Therapies, Inc. (NASDAQ: TSHA) (“Taysha”), a clinical-stage gene therapy company, pursuant to a Loan and Security Agreement dated November 13, 2023, by and among Taysha, the lenders party thereto from time to time (the “Lenders”), and Trinity, as administrative agent and collateral agent for the Lenders.
Related news for (TSHA)
- Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program
- 24/7 Market News Snapshot 29 May, 2025 – Taysha Gene Therapies, Inc. Common Stock (NASDAQ:TSHA)
- Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
- Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102
- Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants